XML 39 R12.htm IDEA: XBRL DOCUMENT

DISTRIBUTION AGREEMENTS AND MAJOR CUSTOMERS	3 Months Ended
DISTRIBUTION AGREEMENTS AND MAJOR CUSTOMERS	Mar. 31, 2013
Distribution Agreements and Major Customer [Abstract]
DISTRIBUTION AGREEMENTS AND MAJOR CUSTOMERS	NOTE G - DISTRIBUTION AGREEMENTS AND MAJOR CUSTOMERS Brachytherapy Seed Distribution Agreements Our brachytherapy seed business sells our TheraSeed® and AgX100® devices directly to healthcare providers and to third-party distributors. Under our TheraSeed® third-party distribution agreements, we are the exclusive palladium-103 seed supplier for the treatment of prostate cancer for each distributor, and each distributor has the non-exclusive right to sell TheraSeed® in the U.S. and Canada. Certain agreements also provide distributors with rights to distribute TheraSeed® for the treatment of solid localized tumors other than in the prostate and with rights to distribute to certain locations outside of North America. Such applications (non-prostate and outside of North America) have not been material. Our principal non-exclusive distribution agreement is with C. R. Bard (“Bard”). Our agreement with Bard (the “Bard Agreement”) provides for automatic one year extensions of the term, unless either party gives notice of its intent not to renew at least twelve months prior to the end of the current term. The current term expires December 31, 2014 and will be automatically extended for one additional year unless either party gives notice of its intent not to extend by December 31, 2013. Major Customers Sales to Bard under the Bard Agreement represented approximately 23% and 29% of total brachytherapy seed segment revenue for the quarters ended March 31, 2013 and 2012, respectively. No other single distributor represented 10% or more of brachytherapy seed segment revenues in the first quarter of 2013 or 2012. Accounts receivable from Bard represented approximately18% of brachytherapy accounts receivable at March 31, 2013. At December 31, 2012, accounts receivable from Bard under the Bard Agreement represented approximately 16% of brachytherapy accounts receivable. One surgical products customer represented 10% of surgical products accounts receivable.